Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21933316 | 1.00 | MAPT (0.50) | MAPTLMNAALDH1A1PDK2NAMPT | |
| SCHEMBL30906239 | 0.96 | MAPT (0.47) | MAPTLMNAALDH1A1PDK2NAMPT | |
| SCHEMBL20046718 | 0.91 | MAPT (0.50) | MAPTLMNAALDH1A1PDK2NAMPT | |
| SCHEMBL20231910 | 0.88 | MAPT (0.52) | MAPTLMNAALDH1A1PDK2NAMPT | |
| SCHEMBL30678672 | 0.88 | MAPT (0.52) | MAPTLMNAALDH1A1PDK2NAMPT | |
| SCHEMBL31707418 | 0.88 | GPR119 (0.48) | ALDH1A1NR1H2NR1H3GPR119 | |
| SCHEMBL25202645 | 0.87 | CYP11B2 (0.41) | MAPTLMNAALDH1A1PDK2NR1H2 | |
| SCHEMBL22454337 | 0.87 | CYP3A4 (0.47) | ALDH1A1PDK2SMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL30423051 | 0.87 | CYP11B2 (0.41) | MAPTLMNAALDH1A1PDK2NR1H2 | |
| SCHEMBL24951416 | 0.87 | MAPT (0.51) | MAPTLMNAALDH1A1PDK2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235298-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING THIAZOLYL DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235331-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615833-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4596538-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025137391-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137393-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASES 2, 4, AND 6 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025039774-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | 泰诺瑞(天津)生物科技有限责任公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024102849-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023037268-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | MAPT 4381/4885LMNA 1761/4885ALDH1A1 3471/4885 |
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | MDH2, MDH1, GOT1 | MAPT 1017/4885LMNA 3851/4885ALDH1A1 565/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | MAPT 2877/4885LMNA 2421/4885ALDH1A1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.